Effects of Bexarotene on Breast Cancer in Mice
Author Information
Author(s): Abba Martin C, Hu Yuhui, Levy Carla C, Gaddis Sally, Kittrell Frances S, Zhang Yun, Hill Jamal, Bissonnette Reid P, Medina Daniel, Brown Powel H, Marcelo Aldaz C
Primary Institution: The University of Texas M.D. Anderson Cancer Center
Hypothesis
The study aims to profile the genes modulated by bexarotene on mammary gland from three transgenic mouse mammary cancer models to elucidate its molecular mechanism of action.
Conclusion
Bexarotene affects multiple cellular pathways related to cancer prevention, including protein biosynthesis and mitochondrial bioenergetics.
Supporting Evidence
- Bexarotene treatment resulted in the identification of 236, 283, and 290 differentially regulated transcripts in the three mouse models.
- 89 genes were found to be dysregulated across the three transgenic mouse mammary models.
- Bexarotene significantly reduced tumor incidence by 75% in the MMTV-ErbB2 model.
Takeaway
Bexarotene is a medicine that helps prevent breast cancer in mice by changing how certain genes work.
Methodology
The study used Serial Analysis of Gene Expression (SAGE) to profile the transcriptome of mammary cells from treated and control mice.
Limitations
The study is based on mouse models, which may not fully represent human breast cancer.
Participant Demographics
Transgenic mouse models including p53-null, MMTV-ErbB2, and C3(1)-SV40.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website